期刊文献+

骨髓病理检查在全血细胞减少性疾病中的应用价值 被引量:12

Clinical Value of Bone Marrow Histopathology in Pancytopenia Disease
原文传递
导出
摘要 目的探讨骨髓病理检查在全血细胞减少性疾病诊断及鉴别诊断中的临床价值。方法回顾性分析医院门诊及住院205例全血细胞减少性疾病患者临床资料。对患者在骨髓形态学检查的基础上加做骨髓病理检查。结果骨髓病理检查在再生障碍性贫血、骨髓增生异常综合征、骨髓纤维化、急性造血功能停滞、多发性骨髓瘤、骨髓转移癌、低增生急性白血病、缺铁性贫血的诊断价值明显优于骨髓形态学检查;同时发现骨髓病理对指导治疗有较好的临床价值。结论骨髓病理检查可作为全血细胞减少性疾病的诊断及鉴别诊断指标,亦有助于指导治疗。 Objective To investigate the clinical value of bone marrow histopathology in the diagnosis and differential diagno- sis to the pancytopenia disease. Methods The clinical data'of 205 cases of pancytopenia( inpatients and outpatient) were ana-lyzed retrospectively. The bone marrow samples were examined by histopathology. Results The diagnostic value of bone marrow histopathology examinations in aplastie anemia, myelodysplastic syndrome ,bone marrow fibrosis ,acute hematopoietic dysfunction, iron deficiency anemia,low proliferative acute leukemia, multiple myeloma and bone marrow metastases was super to bone marrow morphological examinations. Conclusion The bone marrow histopathology will probably indicate the activity of the diagnosis and differential diagnosis to the pancytopenia disease. The detection of serum fcrritin will be helpful to the therapeutic effect of anae-mia disease.
出处 《中华全科医学》 2013年第2期189-191,共3页 Chinese Journal of General Practice
关键词 病理组织学 再生障碍性贫血 诊断 鉴别诊断 Histopathology Aplastie anemia Diagnosis Differential diagnosis
  • 相关文献

参考文献10

二级参考文献57

共引文献47

同被引文献109

  • 1祝彪,张晋林,王小东,王春森.单一使用沙利度胺治疗骨髓增生异常综合征的疗效观察[J].中国药业,2007,16(11):46-47. 被引量:3
  • 2张之南主编.血液病学[M].北京:人民卫生出版杜,2000.
  • 3Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy[J]. Blood,2000,96:2 943 - 2 950.
  • 4Nicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications [J]. Blood,2002, 99:4 525 -4 530.
  • 5Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myeloflbrosis with myeloid metaolasia [ J ]. Br J Haematol, 2002,117 (2) : 288,296.
  • 6Strupp C, Germing U, Aivado M. Thalidomide for the treatment of patients with myelodysplastic syndromes [ J ]. Leukemia, 2002,16 : 1 - 6.
  • 7Deborah A Thomas, Francis J Giles, Maher Albitar. Thalidomide Thera- py for Myelofibrosis with Myeloid Metaplasia[ J]. Cancer, 2006,106 : 1 974 - 1 984.
  • 8Mesa RA, Elliott MA, Schroeder G, et al. Durable responses to thalido- mide- based dmg therapy for myelofibrosis withmyeloid metaplasia [ J ]. Mayo Clin Proc,2004,79 (7) :883 -889.
  • 9Mesa RA,David P Steensma,Animesh Pardanani,et al. Aphase 2 tri- al of combination low- dose thalidomide and prednisone for the treat-ment of myelofibrosis with myeloid metaplasia[J]. Blood,2003, 101: 2 534-2541.
  • 10Weinkove JR, Reilly JT, MeMullin MF, et al. Low-dose thalidomide in myclofibrosis[J]. Haematologiea,2008,93 (7) : 1 100 - 1 101.

引证文献12

二级引证文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部